ESC 2018 – J&J not downhearted after Xarelto stumbles

This year’s European Society of Cardiology meeting dealt two blows to Johnson & Johnson’s label-expansion strategy for its Bayer-partnered blood thinner, Xarelto. But Jim List, head of the company’s cardiovascular and metabolism division, does not believe that this spells the end – at least not in one of the indications tested, the prevention of venous thromboembolism in medically ill patients.